Ask about this productRelated genes to: ATP6V1G2 antibody
- Gene:
- ATP6V1G2 NIH gene
- Name:
- ATPase H+ transporting V1 subunit G2
- Previous symbol:
- ATP6G, ATP6G2
- Synonyms:
- Vma10, NG38, Em:AC004181.3
- Chromosome:
- 6p21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1997-10-10
- Date modifiied:
- 2016-10-05
Related products to: ATP6V1G2 antibody
Related articles to: ATP6V1G2 antibody
- Alzheimer's disease (AD) lacks effective early diagnostic tools. N-glycosylation dysregulation involving the enzyme MGAT3 is implicated in AD pathogenesis, with untapped clinical potential for biomarker development. - Source: PubMed
Publication date: 2026/01/08
Shi GuoXunJu FengDong QiGangFang Ye - Hsa-miR-99a has been linked to the advancement of several malignancies, including colorectal cancer (CRC). This investigation seeks to elucidate its function and regulatory network in CRC. - Source: PubMed
Publication date: 2026/03/17
Yang XuejingZhang TingtingSun HuFeng HuijingSong Dong - LncRNA-disease association (LDA) identification can provide valuable insights for understanding disease pathogenesis. Existing most deep learning-based LDA prediction models remain limitations in effectively fusing various features of lncRNAs and diseases and accurately classifying unknown lncRNA-disease pairs (LDPs). Here, we introduce a deep learning-based LDA prediction frame work named LDA-RMGPB based on multi-representation fusion and boosting with Gaussian process. First, a randomized singular value decomposition model is presented to extract LDP linear features. Subsequently, a masked graph autoencoder is exploited to learn LDP nonlinear features. Finally, a boosting algorithm with Gaussian process takes the concatenation of LDP linear and nonlinear features as inputs and classifies unlabeled LDPs. To measure the LDA-RMGPB performance, we performed a series of experiments. Using six evaluation metrics, under four different 5-fold cross-validation strategies (i.e., cross validations on lncRNAs, diseases, LDPs, independent lncRNAs and inde pendent diseases), LDA-RMGPB greatly surpassed seven state-of-the-art prediction methods on two LDA datasets. Further analysis, including ablation study, CeRNA theory analysis, lncRNA-related therapeutic drug analysis, and survival analysis, elucidated that LDA-RMGPB achieved superior LDA identification ability. Moreover, we predicted that lncRNAs ATP6V1G2-DDX39B and PSORS1C3 could have dense linkages with breast cancer and prostatic neoplasms, respectively. We anticipate that LDA-RMGPB contributes to the discovery of novel therapeutic molecular targets across diverse diseases. LDA-RMGPB is freely available at https://github.com/plhhnu/LDA-RMGPB. - Source: PubMed
Publication date: 2026/03/10
Liu LonglongHuang LiangliangBai ZongzhengJiang YanPeng Lihong - High levels of HBV DNA and HBsAg titres increase the risk of mother-to-child transmission. Development of adaptive immunity post HBV vaccination in neonates born to HBsAg-positive mothers may be determined by maternal HBsAg titres. We analysed pre- and post-HBV vaccination immune status in neonates. - Source: PubMed
Pahwa PrabhjyotiSingh RavinderChattopadhyay ParthaMehta PriyankaVyas Ashish KumarPatra ShardaTyagi ShakunPandey RajeshSarin Shiv KumarTrehanpati Nirupama - To identify new targets for protein-based treatments in psoriasis and evaluate the possible negative impacts of these druggable proteins. - Source: PubMed
Publication date: 2025/10/10
Zheng PingCao YanyunWang AoYi Ke